Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

Summary: This was the first clinical trial exclusively performed in patients with EGPA. Compared to prednisone alone, patients with EGPA receiving mepolizumab had more weeks in remission and were able to taper prednisone to lower doses.

Participating Penn Investigator(s): Dr. Peter Merkel

Journal: New England Journal of Medicine, 2017. View Publication.

Disease(s): Eosinophilic Granulomatosis with Polyangiitis (EGPA)